{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:47:59Z","timestamp":1761007679234,"version":"build-2065373602"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,20]]},"DOI":"10.7759\/cureus.94987","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T15:45:56Z","timestamp":1760975156000},"source":"Crossref","is-referenced-by-count":0,"title":["Antineutrophil Cytoplasmic Antibody (ANCA) Vasculitis, Fatigue, and Treatment With Avacopan: A Case Series"],"prefix":"10.7759","author":[{"given":"Carl","family":"Schulze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220207","article-title":"Vasculitis: what have we learned in the last 50 years?","volume":"49","author":"Carette S","year":"2022","unstructured":"Carette S. Vasculitis: what have we learned in the last 50 years?. J Rheumatol. 2022, 49:848-52. 10.3899\/jrheum.220207","journal-title":"J Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1409129","article-title":"Treatment goals in ANCA-associated vasculitis: defining success in a new era","volume":"15","author":"Alberici F","year":"2024","unstructured":"Alberici F, Tedesco M, Popov T, Balcells-Oliver M, Mescia F. Treatment goals in ANCA-associated vasculitis: defining success in a new era. Front Immunol. 2024, 15:1409129. 10.3389\/fimmu.2024.1409129","journal-title":"Front Immunol"},{"key":"ref3","unstructured":"Search orphan drug designations and approvals. (2014). Accessed. August 14, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=432014."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne DR","year":"2017","unstructured":"Jayne DR, Bruchfeld AN, Harper L, et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017, 28:2756-67. 10.1681\/ASN.2016111179","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel PA","year":"2020","unstructured":"Merkel PA, Niles J, Jimenez R, et al.. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020, 2:662-71. 10.1002\/acr2.11185","journal-title":"ACR Open Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne DR","year":"2021","unstructured":"Jayne DR, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021, 384:599-609. 10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"key":"ref7","unstructured":"Drugs@FDA. FDA-approved drugs. Avacopan. (2024). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102708","article-title":"Comorbidities and health-related quality of life in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"20","author":"Mercuzot C","year":"2021","unstructured":"Mercuzot C, Letertre S, Daien CI, et al.. Comorbidities and health-related quality of life in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Autoimmun Rev. 2021, 20:102708. 10.1016\/j.autrev.2020.102708","journal-title":"Autoimmun Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190113","article-title":"The longitudinal course of fatigue in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"47","author":"O'Malley L","year":"2020","unstructured":"O'Malley L, Druce KL, Chanouzas D, et al.. The longitudinal course of fatigue in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2020, 47:572-9. 10.3899\/jrheum.190113","journal-title":"J Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05398-5","article-title":"Vasculitis patient journey: a scoping review of patient experiences with vasculitis","volume":"40","author":"Gill N","year":"2021","unstructured":"Gill N, Tervaert JW, Yacyshyn E. Vasculitis patient journey: a scoping review of patient experiences with vasculitis. Clin Rheumatol. 2021, 40:1697-708. 10.1007\/s10067-020-05398-5","journal-title":"Clin Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01827","article-title":"Fatigue, sleep, and autoimmune and related disorders","volume":"10","author":"Zielinski MR","year":"2019","unstructured":"Zielinski MR, Systrom DM, Rose NR. Fatigue, sleep, and autoimmune and related disorders. Front Immunol. 2019, 10:1827. 10.3389\/fimmu.2019.01827","journal-title":"Front Immunol"},{"key":"ref12","unstructured":"Chronic fatigue-a survey to help define the gap among autoimmune patients of color. Accessed. August 8, 2025: https:\/\/autoimmune.org\/research\/chronic-fatigue\/."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100460","article-title":"Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) and fibromyalgia: PR3-versus MPO-ANCA-associated vasculitis, an exploratory cross-sectional study","volume":"20","author":"van Eeden C","year":"2023","unstructured":"van Eeden C, Mohazab N, Redmond D, et al.. Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) and fibromyalgia: PR3-versus MPO-ANCA-associated vasculitis, an exploratory cross-sectional study. Lancet Reg Health Am. 2023, 20:100460. 10.1016\/j.lana.2023.100460","journal-title":"Lancet Reg Health Am"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq098","article-title":"Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis","volume":"49","author":"Basu N","year":"2010","unstructured":"Basu N, Jones GT, Fluck N, et al.. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology (Oxford). 2010, 49:1383-90. 10.1093\/rheumatology\/keq098","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22827","article-title":"Physical fatigue, fitness, and muscle function in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"68","author":"McClean A","year":"2016","unstructured":"McClean A, Morgan MD, Basu N, Bosch JA, Nightingale P, Jones D, Harper L. Physical fatigue, fitness, and muscle function in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2016, 68:1332-9. 10.1002\/acr.22827","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2116002","article-title":"Fatigue in ANCA-associated vasculitis (AAV) and systemic sclerosis (SSc): similarities with myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). A critical review of the literature","volume":"18","author":"van Eeden C","year":"2022","unstructured":"van Eeden C, Osman MS, Cohen Tervaert JW. Fatigue in ANCA-associated vasculitis (AAV) and systemic sclerosis (SSc): similarities with myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). A critical review of the literature. Expert Rev Clin Immunol. 2022, 18:1049-70. 10.1080\/1744666X.2022.2116002","journal-title":"Expert Rev Clin Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.08.2008.0819","article-title":"Chronic fatigue syndrome and complement activation","volume":"2009","author":"Geller RD","year":"2009","unstructured":"Geller RD, Giclas PC. Chronic fatigue syndrome and complement activation. BMJ Case Rep. 2009, 2009:bcr0820080819. 10.1136\/bcr.08.2008.0819","journal-title":"BMJ Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S339660","article-title":"Managing fatigue in patients with paroxysmal nocturnal hemoglobinuria: a patient-focused perspective","volume":"13","author":"Fattizzo B","year":"2022","unstructured":"Fattizzo B, Cavallaro F, Oliva EN, Barcellini W. Managing fatigue in patients with paroxysmal nocturnal hemoglobinuria: a patient-focused perspective. J Blood Med. 2022, 13:327-35. 10.2147\/JBM.S339660","journal-title":"J Blood Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00092-9","article-title":"The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Strand V","year":"2023","unstructured":"Strand V, Jayne DRW, Horomanski A, Yue H, Bekker P, Merkel PA, ADVOCATE Study Group. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol. 2023, 5:451-60. 10.1016\/S2665-9913(23)00092-9","journal-title":"Lancet Rheumatol"},{"key":"ref20","unstructured":"Drugs@FDA. FDA-approved drugs. Eculizumab. (2007). Accessed: September 6, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"ref21","unstructured":"Drugs@FDA. FDA-approved drugs. Ravilizumab. (2022). Accessed: September 6, 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen H","year":"2019","unstructured":"Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019, 28:2247-54. 10.1007\/s11136-019-02148-2","journal-title":"Qual Life Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh M","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, et al.. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020, 382:622-31. 10.1056\/NEJMoa1803537","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.74105","article-title":"Reduction of chronic fatigue through transcranial direct current stimulation and low-intensity aerobic exercise: a case study of two patients with granulomatosis with polyangiitis","volume":"16","author":"Dos Santos AM","year":"2024","unstructured":"Dos Santos AM, De Andrade VP, Silva PR, Grecco MV, D'Andrea Greve JM, Shinjo SK. Reduction of chronic fatigue through transcranial direct current stimulation and low-intensity aerobic exercise: a case study of two patients with granulomatosis with polyangiitis. Cureus. 2024, 16:e74105. 10.7759\/cureus.74105","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/413913-antineutrophil-cytoplasmic-antibody-anca-vasculitis-fatigue-and-treatment-with-avacopan-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T15:45:57Z","timestamp":1760975157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/413913-antineutrophil-cytoplasmic-antibody-anca-vasculitis-fatigue-and-treatment-with-avacopan-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.94987","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,20]]}}}